An In-situ Detection for MicroRNA

NCT06529614 · tracked via the Priya Life Science China tracker

Sponsor

Tongji Hospital

Phase

—

Started

2024-07-20

Last updated

2025-10-06

Condition(s) studied

Breast Cancer

Investigational drug(s) / intervention(s)

In-situ detection for Micro-RNA

In-situ detection for Micro-RNA: a new in-situ detection methods for Micro-RNA

Study summary

We designed a new in-site detection method for MicroRNA in the serum of patients with breast cancer.

Eligibility

Sex

FEMALE

Min age

18 Years

Max age

75 Years

Healthy volunteers

Accepted

Inclusion Criteria: Healthy without serious diseases \- Exclusion Criteria: * situations that may affect the results

Primary outcome measure(s)

Sensitivity and specificity of test — 8 months

Trial sites (1)

Facility	City	Region	Status
Tongji Hospital	Wuhan	Hubei	Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06529614 on ClinicalTrials.gov ↗ ← All trials in China